The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
